Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
Steuer CE, Hayashi H, Su WC, Nishio M, Johnson ML, Kim DW, Massarelli E, Felip E, Gold KA, Murakami H, Baik CS, Kim SW, Smit EF, Fujimura M, Fan PD, Truchon K, Su X, Sternberg DW, Jänne PA. Steuer CE, et al. Among authors: johnson ml. J Clin Oncol. 2025 Jun 24:JCO2402744. doi: 10.1200/JCO-24-02744. Online ahead of print. J Clin Oncol. 2025. PMID: 40554742
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, Şendur MAN, Czyżewicz G, Caro RB, Lee KH, Johnson ML, Karadurmuş N, Grohé C, Baka S, Csőszi T, Ahn JS, Califano R, Yang TY, Kemal Y, Ballinger M, Cuchelkar V, Graupner V, Lin YC, Chakrabarti D, Bhatt K, Cai G, Iannone R, Reck M; IMforte investigators. Paz-Ares L, et al. Among authors: johnson ml. Lancet. 2025 Jun 14;405(10495):2129-2143. doi: 10.1016/S0140-6736(25)01011-6. Epub 2025 Jun 2. Lancet. 2025. PMID: 40473449 Clinical Trial.
In vitro evaluation of slow-release urea compounds.
Ma SW, Arce-Cordero JA, Lobo RR, Sarmikasoglou E, Vinyard JR, Johnson ML, Bahman A, Dagaew G, Sumadong P, Siregar MU, Salas-Solis GK, Estes KA, Vyas D, Faciola AP. Ma SW, et al. Among authors: johnson ml. J Dairy Sci. 2025 Jul;108(7):7023-7035. doi: 10.3168/jds.2024-25882. Epub 2025 May 8. J Dairy Sci. 2025. PMID: 40348372 Free article.
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON.
Peters S, Oliner KS, L'Hernault A, Ratcliffe M, Madison H, Lai Z, Stewart R, Mann H, Lowery C, Garon EB, Mok T, Johnson ML. Peters S, et al. Among authors: johnson ml. ESMO Open. 2025 May;10(5):105058. doi: 10.1016/j.esmoop.2025.105058. Epub 2025 May 6. ESMO Open. 2025. PMID: 40334315 Free PMC article. Clinical Trial.
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial.
Cho BC, Lu S, Lee MA, Song Z, Park JJ, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Loong HH, Chen C, Wang J, Shen Y, Fan Z, Chen Q, Wang H, Zhang J, Chen ZJ, Johnson ML, Mok T. Cho BC, et al. Among authors: johnson ml. Nat Med. 2025 Apr 29. doi: 10.1038/s41591-025-03688-6. Online ahead of print. Nat Med. 2025. PMID: 40301557
1,099 results